Sandra Calvin - 31 Jan 2023 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
SVP, Chief Accounting Officer
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
31 Jan 2023
Net transactions value
-$44,419
Form type
4
Filing time
02 Feb 2023, 17:53:33 UTC
Previous filing
26 Jan 2023
Next filing
12 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Award $0 +10,000 +29% $0.000000 44,836 31 Jan 2023 Direct F1
transaction TVTX Common Stock Sale $36,348 -1,671 -3.7% $21.75 43,165 01 Feb 2023 Direct F2
transaction TVTX Common Stock Sale $8,071 -360 -0.83% $22.42 42,805 02 Feb 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Employee stock option (right to buy) Award $0 +20,000 $0.000000 20,000 31 Jan 2023 Common Stock 20,000 $22.40 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
F2 Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
F3 The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
F4 One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.